JIUYUAN GENE (02566) intends to use up to 100 million yuan to repurchase shares.

date
18:36 02/12/2025
avatar
GMT Eight
Gene Source Technology Limited (02566) announced that the board of directors resolved on December 2, 2025, depending on market conditions, the company intends to use up to RMB 100 million to repurchase a maximum of approximately 10,909,700 H shares on the open market with its own funds from the date of this announcement until the expiration of the repurchase authorization period. The actual repurchase price per H share for each repurchase shall not exceed 5% or more of the average closing price of the H shares in the five trading days immediately preceding each repurchase. H shares repurchased under the repurchase authorization may be cancelled, held as treasury shares, or used for stock incentive plans.
JIUYUAN GENE (02566) announced that the board of directors decided on December 2, 2025 to potentially repurchase up to 10.97 million H shares with a maximum amount of RMB 100 million on the open market using company funds, depending on market conditions. The actual repurchase price per H share in each repurchase transaction shall not exceed a premium of 5% or more above the average closing price of the H shares in the five trading days preceding each repurchase. The repurchased H shares may be cancelled, held as treasury shares, or used for stock incentive plans. The company's current cash flow is strong, and overall financial condition is stable, meeting the needs for the company's continued business development. The board believes that the current share price does not fully reflect the company's intrinsic value and business prospects. Therefore, repurchasing shares at this time will demonstrate confidence in the company's business prospects and growth potential, ultimately benefiting the company and creating value for shareholders.